- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Submit a Manuscript
- Subscription Information
- Table of Contents
The Scientific World Journal
Volume 2013 (2013), Article ID 703568, 8 pages
Alternative Splicing for Diseases, Cancers, Drugs, and Databases
1Department of Radiation Oncology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan
2Department of Radiation Oncology, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan
3Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan
4Department of Biotechnology, Kaohsiung Medical University, Kaohsiung 807, Taiwan
5Institute of Clinical Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan
6Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung 807, Taiwan
7Bioresource Collection and Research Center, Food Industry Research and Development Institute, Hsinchu 300, Taiwan
8Institute of Biomedical Science, National Sun Yat-Sen University, Kaohsiung 807, Taiwan
9Graduate Institute of Natural Products, Kaohsiung Medical University, Kaohsiung 807, Taiwan
10Department of Biomedical Science and Environmental Biology, Kaohsiung Medical University, Kaohsiung 807, Taiwan
Received 1 April 2013; Accepted 30 April 2013
Academic Editors: F. Alvarez-Valin and A. Komiya
Copyright © 2013 Jen-Yang Tang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- D. Brett, H. Pospisil, J. Valcárcel, J. Reich, and P. Bork, “Alternative splicing and genome complexity,” Nature Genetics, vol. 30, no. 1, pp. 29–30, 2002.
- C. Ghigna, M. De Toledo, S. Bonomi et al., “Pro-metastatic splicing of Ron proto-oncogene mRNA can be reversed: therapeutic potential of bifunctional oligonucleotides and indole derivatives,” RNA Biology, vol. 7, no. 4, pp. 495–503, 2010.
- K. F. Mittendorf, C. L. Deatherage, M. D. Ohi, and C. R. Sanders, “Tailoring of membrane proteins by alternative splicing of pre-mRNA,” Biochemistry, vol. 51, no. 28, pp. 5541–5556, 2012.
- R. F. Luco, M. Allo, I. E. Schor, A. R. Kornblihtt, and T. Misteli, “Epigenetics in alternative pre-mRNA splicing,” Cell, vol. 144, no. 1, pp. 16–26, 2011.
- M. G. Poulos, R. Batra, K. Charizanis, and M. S. Swanson, “Developments in RNA splicing and disease,” Cold Spring Harbor Perspectives in Biology, vol. 3, no. 1, Article ID a000778, 2011.
- J. D. Mills and M. Janitz, “Alternative splicing of mRNA in the molecular pathology of neurodegenerative diseases,” Neurobiology of Aging, vol. 33, no. 5, pp. 1011–1024, 2012.
- K. Yap and E. V. Makeyev, “Regulation of gene expression in mammalian nervous system through alternative pre-mRNA splicing coupled with RNA quality control mechanisms,” Molecular and Cellular Neuroscience, 2013.
- R. H. Fu, S. P. Liu, S. J. Huang et al., “Aberrant alternative splicing events in Parkinson's disease,” Cell Transplantation, vol. 22, no. 4, pp. 653–661, 2013.
- J. Pearn, “Classification of spinal muscular atrophies,” Lancet, vol. 1, no. 8174, pp. 919–922, 1980.
- J. Zhou, X. Zheng, and H. Shen, “Targeting RNA-splicing for SMA treatment,” Molecules and Cells, vol. 33, no. 3, pp. 223–228, 2012.
- Y. Zhao, M. Koebis, S. Suo, S. Ohno, and S. Ishiura, “Regulation of the alternative splicing of sarcoplasmic reticulum Ca2+-ATPase1 (SERCA1) by phorbol 12-myristate 13-acetate (PMA) via a PKC pathway,” Biochemical and Biophysical Research Communications, vol. 423, no. 2, pp. 212–217, 2012.
- T. A. Cooper, “Alternative splicing regulation impacts heart development,” Cell, vol. 120, no. 1, pp. 1–2, 2005.
- E. Lara-Pezzi, A. Dopazo, and M. Manzanares, “Understanding cardiovascular disease: a journey through the genome (and what we found there),” Disease Models & Mechanisms, vol. 5, no. 4, pp. 434–443, 2012.
- V. Y. Bogdanov, “Blood coagulation and alternative pre-mRNA splicing: an overview,” Current Molecular Medicine, vol. 6, no. 8, pp. 859–869, 2006.
- M. W. Medina and R. M. Krauss, “Alternative splicing in the regulation of cholesterol homeostasis,” Current Opinion in Lipidology, vol. 24, no. 2, pp. 147–152, 2013.
- K. Endo-Umeda, S. Uno, K. Fujimori et al., “Differential expression and function of alternative splicing variants of human liver X receptor alpha,” Molecular Pharmacology, vol. 81, no. 6, pp. 800–810, 2012.
- M. Manetti, S. Guiducci, L. Ibba-Manneschi, and M. Matucci-Cerinic, “Impaired angiogenesis in systemic sclerosis: the emerging role of the antiangiogenic VEGF(165)b splice variant,” Trends in Cardiovascular Medicine, vol. 21, no. 7, pp. 204–210, 2011.
- X. Xu, D. Yang, J. H. Ding et al., “ASF/SF2-regulated CaMKIIδ alternative splicing temporally reprograms excitation-contraction coupling in cardiac muscle,” Cell, vol. 120, no. 1, pp. 59–72, 2005.
- O. Fedorov, K. Huber, A. Eisenreich et al., “Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing,” Chemistry & Biology, vol. 18, no. 1, pp. 67–76, 2011.
- S. W. Kong, Y. W. Hu, J. W. K. Ho et al., “Heart failure-associated changes in RNA splicing of sarcomere genes,” Circulation, vol. 3, no. 2, pp. 138–146, 2010.
- R. Burkhardt, E. E. Kenny, J. K. Lowe et al., “Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 11, pp. 2078–2084, 2008.
- H. Zhu, H. M. Tucker, K. E. Grear et al., “A common polymorphism decreases low-density lipoprotein receptor exon 12 splicing efficiency and associates with increased cholesterol,” Human Molecular Genetics, vol. 16, no. 14, pp. 1765–1772, 2007.
- R. J. Schmidt, Y. Zhang, Y. Zhao et al., “A novel splicing variant of proprotein convertase subtilisin/kexin type 9,” DNA and Cell Biology, vol. 27, no. 4, pp. 183–189, 2008.
- G. Gil, J. R. Smith, J. L. Goldstein, and M. S. Brown, “Optional exon in the 5′-untranslated region of 3-hydroxy-3-methylglutaryl coenzyme A synthase gene: conserved sequence and splicing pattern in humans and hamsters,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 7, pp. 1863–1866, 1987.
- S. M. Houten, J. Koster, G. J. Romeijn et al., “Organization of the mevalonate kinase (MVK) gene and identification of novel mutations causing mevalonic aciduria and hyperimmunoglobulinaemia D and periodic fever syndrome,” European Journal of Human Genetics, vol. 9, no. 4, pp. 253–259, 2001.
- D. Kaida, T. Schneider-Poetsch, and M. Yoshida, “Splicing in oncogenesis and tumor suppression,” Cancer Science, vol. 103, no. 9, pp. 1611–1616, 2012.
- R. M. Hagen and M. R. Ladomery, “Role of splice variants in the metastatic progression of prostate cancer,” Biochemical Society Transactions, vol. 40, no. 4, pp. 870–874, 2012.
- J. Sampath and L. M. Pelus, “Alternative splice variants of survivin as potential targets in cancer,” Current Drug Discovery Technologies, vol. 4, no. 3, pp. 174–191, 2007.
- K. Miura, W. Fujibuchi, and I. Sasaki, “Alternative pre-mRNA splicing in digestive tract malignancy,” Cancer Science, vol. 102, no. 2, pp. 309–316, 2011.
- N. Okumura, H. Yoshida, Y. Kitagishi, Y. Nishimura, and S. Matsuda, “Alternative splicings on p53, BRCA1 and PTEN genes involved in breast cancer,” Biochemical and Biophysical Research Communications, vol. 413, no. 3, pp. 395–399, 2011.
- M. Talieri, M. Devetzi, A. Scorilas et al., “Human kallikrein-related peptidase 12 (KLK12) splice variants expression in breast cancer and their clinical impact,” Tumor Biology, vol. 33, no. 4, pp. 1075–1084, 2012.
- C. Tammaro, M. Raponi, D. I. Wilson, and D. Baralle, “BRCA1 exon 11 alternative splicing, multiple functions and the association with cancer,” Biochemical Society Transactions, vol. 40, no. 4, pp. 768–772, 2012.
- J. Zhong, R. X. Cao, X. Y. Zu et al., “Identification and characterization of novel spliced variants of PRMT2 in breast carcinoma,” FEBS Journal, vol. 279, no. 2, pp. 316–335, 2012.
- H. Albert, S. Santos, E. Battaglia, M. Brito, C. Monteiro, and D. Bagrel, “Differential expression of CDC25 phosphatases splice variants in human breast cancer cells,” Clinical Chemistry and Laboratory Medicine, vol. 49, no. 10, pp. 1707–1714, 2011.
- S. Sebban, R. Golan-Gerstl, R. Karni, O. Vaksman, B. Davidson, and R. Reich, “Alternatively spliced lysyl oxidase-like 4 isoforms have a pro-metastatic role in cancer,” Clinical and Experimental Metastasis, vol. 30, no. 1, pp. 103–117, 2013.
- Y. Wang, D. W. Chan, V. W. S. Liu, P. M. Chiu, and H. Y. S. Ngan, “Differential functions of growth factor receptor-bound protein 7 (GRB7) and its variant GRB7v in ovarian carcinogenesis,” Clinical Cancer Research, vol. 16, no. 9, pp. 2529–2539, 2010.
- S. Haile and M. D. Sadar, “Androgen receptor and its splice variants in prostate cancer,” Cellular and Molecular Life Sciences, vol. 68, no. 24, pp. 3971–3981, 2011.
- P. A. Usher, A. M. Sieuwerts, A. Bartels et al., “Identification of alternatively spliced TIMP-1 mRNA in cancer cell lines and colon cancer tissue,” Molecular Oncology, vol. 1, no. 2, pp. 205–215, 2007.
- D. C. Gotley, J. Fawcett, M. D. Walsh, J. A. Reeder, D. L. Simmons, and T. M. Antalis, “Alternatively spliced variants of the cell adhesion molecule CD44 and tumour progression in colorectal cancer,” British Journal of Cancer, vol. 74, no. 3, pp. 342–351, 1996.
- R. Pio and L. M. Montuenga, “Alternative splicing in lung cancer,” Journal of Thoracic Oncology, vol. 4, no. 6, pp. 674–678, 2009.
- D. Moretti, B. Del Bello, E. Cosci, M. Biagioli, C. Miracco, and E. Maellaro, “Novel variants of muscle calpain 3 identified in human melanoma cells: cisplatin-induced changes in vitro and differential expression in melanocytic lesions,” Carcinogenesis, vol. 30, no. 6, pp. 960–967, 2009.
- N. Hanoun, C. Bureau, T. Diab et al., “The SV2 variant of KLF6 is down-regulated in hepatocellular carcinoma and displays anti-proliferative and pro-apoptotic functions,” Journal of Hepatology, vol. 53, no. 5, pp. 880–888, 2010.
- Q. Yi and L. Tang, “Alternative spliced variants as biomarkers of colorectal cancer,” Current Drug Metabolism, vol. 12, no. 10, pp. 966–974, 2011.
- G. S. Omenn, A. K. Yocum, and R. Menon, “Alternative splice variants, a new class of protein cancer biomarker candidates: findings in pancreatic cancer and breast cancer with systems biology implications,” Disease Markers, vol. 28, no. 4, pp. 241–251, 2010.
- Y. Lee, E. R. Gamazon, E. Rebman et al., “Variants affecting exon skipping contribute to complex traits,” PLOS Genetics, vol. 8, no. 10, Article ID e1002998, 2012.
- H. Feng, Z. Qin, and X. Zhang, “Opportunities and methods for studying alternative splicing in cancer with RNA-Seq,” Cancer Letters, 2012.
- G. Li, J. H. Bahn, J. H. Lee et al., “Identification of allele-specific alternative mRNA processing via transcriptome sequencing,” Nucleic Acids Research, vol. 40, no. 13, article e104, 2012.
- L. Xi, A. Feber, V. Gupta et al., “Whole genome exon arrays identify differential expression of alternatively spliced, cancer-related genes in lung cancer,” Nucleic Acids Research, vol. 36, no. 20, pp. 6535–6547, 2008.
- C. Ben-Dov, B. Hartmann, J. Lundgren, and J. Valcárcel, “Genome-wide analysis of alternative pre-mRNA splicing,” Journal of Biological Chemistry, vol. 283, no. 3, pp. 1229–1233, 2008.
- O. Gautschi, D. Ratschiller, M. Gugger, D. C. Betticher, and J. Heighway, “Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation,” Lung Cancer, vol. 55, no. 1, pp. 1–14, 2007.
- G. Lamolle, M. Marin, and F. Alvarez-Valin, “Silent mutations in the gene encoding the p53 protein are preferentially located in conserved amino acid positions and splicing enhancers,” Mutation Research, vol. 600, no. 1-2, pp. 102–112, 2006.
- D. W. Neklason, C. H. Solomon, A. L. Dalton, S. K. Kuwada, and R. W. Burt, “Intron 4 mutation in APC gene results in splice defect and attenuated FAP phenotype,” Familial Cancer, vol. 3, no. 1, pp. 35–40, 2004.
- M. Raponi, J. Kralovicova, E. Copson et al., “Prediction of single-nucleotide substitutions that result in exon skipping: identification of a splicing silencer in BRCA1 exon 6,” Human Mutation, vol. 32, no. 4, pp. 436–444, 2011.
- H. X. Liu, L. Cartegni, M. Q. Zhang, and A. R. Krainer, “A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes,” Nature Genetics, vol. 27, no. 1, pp. 55–58, 2001.
- G. Narla, A. DiFeo, H. L. Reeves et al., “A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk,” Cancer Research, vol. 65, no. 4, pp. 1213–1222, 2005.
- G. Narla, A. Difeo, S. Yao et al., “Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread,” Cancer Research, vol. 65, no. 13, pp. 5761–5768, 2005.
- A. DiFeo, L. Feld, E. Rodriguez et al., “A functional role for KLF6-SV1 in lung adenocarcinoma prognosis and chemotherapy response,” Cancer Research, vol. 68, no. 4, pp. 965–970, 2008.
- J. O. Yang, W. Y. Kim, and J. Bhak, “ssSNPTarget: genome-wide splice-site single nucleotide polymorphism database,” Human Mutation, vol. 30, no. 12, pp. E1010–E1020, 2009.
- A. G. Douglas and M. J. Wood, “RNA splicing: disease and therapy,” Briefings in Functional Genomics, vol. 10, no. 3, pp. 151–164, 2011.
- R. K. Singh and T. A. Cooper, “Pre-mRNA splicing in disease and therapeutics,” Trends in Molecular Medicine, vol. 18, no. 8, pp. 472–482, 2012.
- P. Spitali and A. Aartsma-Rus, “Splice modulating therapies for human disease,” Cell, vol. 148, no. 6, pp. 1085–1088, 2012.
- K. Miura, W. Fujibuchi, and M. Unno, “Splice isoforms as therapeutic targets for colorectal cancer,” Carcinogenesis, vol. 33, no. 12, pp. 2311–2319, 2012.
- J. P. Maciejewski and R. A. Padgett, “Defects in spliceosomal machinery: a new pathway of leukaemogenesis,” British Journal of Haematology, vol. 158, no. 2, pp. 165–173, 2012.
- M. Hagiwara, “Alternative splicing: a new drug target of the post-genome era,” Biochimica et Biophysica Acta, vol. 1754, no. 1-2, pp. 324–331, 2005.
- C. A. Blair and X. Zi, “Potential molecular targeting of splice variants for cancer treatment,” Indian Journal of Experimental Biology, vol. 49, no. 11, pp. 836–839, 2011.
- R. J. Van Alphen, E. A. C. Wiemer, H. Burger, and F. A. L. M. Eskens, “The spliceosome as target for anticancer treatment,” British Journal of Cancer, vol. 100, no. 2, pp. 228–232, 2009.
- S. Bonnal, L. Vigevani, and J. Valcarcel, “The spliceosome as a target of novel antitumour drugs,” Nature Reviews Drug Discovery, vol. 11, no. 11, pp. 847–859, 2012.
- E. S. Barrie, R. M. Smith, J. C. Sanford, and W. Sadee, “mRNA transcript diversity creates new opportunities for pharmacological intervention,” Molecular Pharmacology, vol. 81, no. 5, pp. 620–630, 2012.
- M. L. Zhang, C. L. Lorson, E. J. Androphy, and J. Zhou, “An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA,” Gene Therapy, vol. 8, no. 20, pp. 1532–1538, 2001.
- C. Andreassi, J. Jarecki, J. Zhou et al., “Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients,” Human Molecular Genetics, vol. 10, no. 24, pp. 2841–2849, 2001.
- M. R. Lunn, D. E. Root, A. M. Martino et al., “Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism,” Chemistry and Biology, vol. 11, no. 11, pp. 1489–1493, 2004.
- C. Xu, X. Chen, S. M. Grzeschik, M. Ganta, and C. H. Wang, “Hydroxyurea enhances SMN2 gene expression through nitric oxide release,” Neurogenetics, vol. 12, no. 1, pp. 19–24, 2011.
- C. C. Weihl, A. M. Connolly, and A. Pestronk, “Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy,” Neurology, vol. 67, no. 3, pp. 500–501, 2006.
- C. Y. Yuo, H. H. Lin, Y. S. Chang, W. K. Yang, and J. G. Chang, “5-(N-ethyl-N-isopropyl)-amiloride enhances SMN2 exon 7 inclusion and protein expression in spinal muscular atrophy cells,” Annals of Neurology, vol. 63, no. 1, pp. 26–34, 2008.
- C. Andreassi, C. Angelozzi, F. D. Tiziano et al., “Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy,” European Journal of Human Genetics, vol. 12, no. 1, pp. 59–65, 2004.
- Z. Zhang, O. Kelemen, M. A. Van Santen et al., “Synthesis and characterization of pseudocantharidins, novel phosphatase modulators that promote the inclusion of exon 7 into the SMN (survival of motoneuron) pre-mRNA,” Journal of Biological Chemistry, vol. 286, no. 12, pp. 10126–10136, 2011.
- I. S. K. Harahap, T. Saito, L. P. San et al., “Valproic acid increases SMN2 expression and modulates SF2/ASF and hnRNPA1 expression in SMA fibroblast cell lines,” Brain and Development, 2011.
- S. Zheng, Y. Chen, C. P. Donahue, M. S. Wolfe, and G. Varani, “Structural Basis for Stabilization of the Tau Pre-mRNA Splicing Regulatory Element by Novantrone (Mitoxantrone),” Chemistry and Biology, vol. 16, no. 5, pp. 557–566, 2009.
- J. S. Lewis and V. C. Jordan, “Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance,” Mutation Research, vol. 591, no. 1-2, pp. 247–263, 2005.
- S. L. Lin, L. Y. Yan, X. T. Zhang et al., “ER-α36, a variant of ER-α, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways,” PLoS ONE, vol. 5, no. 2, Article ID e9013, 2010.
- E. Zaharieva, J. K. Chipman, and M. Soller, “Alternative splicing interference by xenobiotics,” Toxicology, vol. 296, pp. 1–12, 2012.
- D. Kaida, H. Motoyoshi, E. Tashiro et al., “Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA,” Nature Chemical Biology, vol. 3, no. 9, pp. 576–583, 2007.
- Y. Kotake, K. Sagane, T. Owa et al., “Splicing factor SF3b as a target of the antitumor natural product pladienolide,” Nature Chemical Biology, vol. 3, no. 9, pp. 570–575, 2007.
- L. Fan, C. Lagisetti, C. C. Edwards, T. R. Webb, and P. M. Potter, “Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing,” ACS Chemical Biology, vol. 6, no. 6, pp. 582–589, 2011.
- A. Corrionero, B. Miñana, and J. Valcárcel, “Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A,” Genes and Development, vol. 25, no. 5, pp. 445–459, 2011.
- R. Furumai, K. Uchida, Y. Komi et al., “Spliceostatin A blocks angiogenesis by inhibiting global gene expression including VEGF,” Cancer Science, vol. 101, no. 11, pp. 2483–2489, 2010.
- H. Nakajima, B. Sato, T. Fujita, S. Takase, H. Terano, and M. Okuhara, “New antitumor substances, FR901463, FR901464 and FR901465: I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities,” Journal of Antibiotics, vol. 49, no. 12, pp. 1196–1203, 1996.
- B. J. Albert, P. A. McPherson, K. O'Brien et al., “Meayamycin inhibits pre-messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells,” Molecular Cancer Therapeutics, vol. 8, no. 8, pp. 2308–2318, 2009.
- J. Woolard, W. Vousden, S. J. Moss et al., “Borrelidin modulates the alternative splicing of VEGF in favour of anti-angiogenic isoforms,” Chemical Science, vol. 2011, no. 2, pp. 273–278, 2011.
- U. Shamim, S. Hanif, A. Albanyan et al., “Resveratrol-induced apoptosis is enhanced in low pH environments associated with cancer,” Journal of Cellular Physiology, vol. 227, no. 4, pp. 1493–1500, 2012.
- J. Jakubikova, D. Cervi, M. Ooi et al., “Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma,” Haematologica, vol. 96, no. 8, pp. 1170–1179, 2011.
- M. A. Markus, F. Z. Marques, and B. J. Morris, “Resveratrol, by modulating RNA processing factor levels, can influence the alternative splicing of pre-mRNAs,” PLoS One, vol. 6, no. 12, Article ID e28926, 2011.
- K. Miura, W. Fujibuchi, and M. Unno, “Splice variants in apoptotic pathway,” Experimental Oncology, vol. 34, no. 3, pp. 212–217, 2012.
- C. Schwerk and K. Schulze-Osthoff, “Regulation of apoptosis by alternative pre-mRNA splicing,” Molecular Cell, vol. 19, no. 1, pp. 1–13, 2005.
- L. Shkreta, U. Froehlich, E. R. Paquet, J. Toutant, S. A. Elela, and B. Chabot, “Anticancer drugs affect the alternative splicing of Bcl-x and other human apoptotic genes,” Molecular Cancer Therapeutics, vol. 7, no. 6, pp. 1398–1409, 2008.
- J. Lee, J. Zhou, X. Zheng et al., “Identification of a novel cis-element that regulates alternative splicing of Bcl-x pre-mRNA,” Biochemical and Biophysical Research Communications, vol. 420, no. 2, pp. 467–472, 2012.
- T. Revil, J. Toutant, L. Shkreta, D. Garneau, P. Cloutier, and B. Chabot, “Protein kinase C-dependent control of Bcl-x alternative splicing,” Molecular and Cellular Biology, vol. 27, no. 24, pp. 8431–8441, 2007.
- J. C. Shultz, R. W. Goehe, D. S. Wijesinghe et al., “Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a,” Cancer Research, vol. 70, no. 22, pp. 9185–9196, 2010.
- C. Puppin, N. Passon, A. Franzoni, D. Russo, and G. Damante, “Histone deacetylase inhibitors control the transcription and alternative splicing of prohibitin in thyroid tumor cells,” Oncology Reports, vol. 25, no. 2, pp. 393–397, 2011.
- S. Wu, C. Li, W. Huang, W. Li, and R. W. Li, “Alternative splicing regulated by butyrate in bovine epithelial cells,” PLoS One, vol. 7, no. 6, Article ID e39182, 2012.
- C. Lee and Q. Wang, “Bioinformatics analysis of alternative splicing,” Briefings in Bioinformatics, vol. 6, no. 1, pp. 23–33, 2005.
- L. D. Florea, “Bioinformatics of alternative splicing and its regulation,” Briefings in Bioinformatics, vol. 7, no. 1, pp. 55–69, 2006.
- N. Kim and C. Lee, “Bioinformatics detection of alternative splicing,” Methods in Molecular Biology, vol. 452, pp. 179–197, 2008.
- H. Ji, Q. Zhou, F. Wen, H. Xia, X. Lu, and Y. Li, “AsMamDB: an alternative splice database of mammals,” Nucleic Acids Research, vol. 29, no. 1, pp. 260–263, 2001.
- Y. H. Huang, Y. T. Chen, J. J. Lai, S. T. Yang, and U. C. Yang, “PALS db: putative alternative splicing database,” Nucleic Acids Research, vol. 30, no. 1, pp. 186–190, 2002.
- C. Lee, L. Atanelov, B. Modrek, and Y. Xing, “ASAP: the alternative splicing annotation project,” Nucleic Acids Research, vol. 31, no. 1, pp. 101–105, 2003.
- H. Pospisil, A. Herrmann, R. H. Bortfeldt, and J. G. Reich, “EASED: Extended Alternatively Spliced EST Database,” Nucleic Acids Research, vol. 32, pp. D70–D74, 2004.
- F. R. Hsu, H. Y. Chang, Y. L. Lin et al., “AVATAR: a database for genome-wide alternative splicing event detection using large scale ESTs and mRNAs,” , Bioinformation, vol. 1, no. 1, pp. 16–18, 2005.
- C. L. Zheng, Y. S. Kwon, L. I. Hai-Ri et al., “MAASE: an alternative splicing database designed for supporting splicing microarray applications,” RNA, vol. 11, no. 12, pp. 1767–1776, 2005.
- H. Zhang, J. Hu, M. Recce, and B. Tian, “PolyA_DB: a database for mammalian mRNA polyadenylation,” Nucleic Acids Research, vol. 33, pp. D116–D120, 2005.
- V. Le Texier, J. J. Riethoven, V. Kumanduri et al., “AltTrans: transcript pattern variants annotated for both alternative splicing and alternative polyadenylation,” BMC Bioinformatics, vol. 7, article 169, 2006.
- R. Kostadinov, N. Malhotra, M. Viotti, R. Shine, L. D'Antonio, and P. Bagga, “GRSDB: a database of quadruplex forming G-rich sequences in alternatively processed mammalian pre-mRNA sequences,” Nucleic Acids Research, vol. 34, pp. D119–124, 2006.
- D. Holste, G. Huo, V. Tung, and C. B. Burge, “HOLLYWOOD: a comparative relational database of alternative splicing,” Nucleic Acids Research, vol. 34, pp. D56–62, 2006.
- S. Stamm, J. J. Riethoven, V. Le Texier et al., “ASD: a bioinformatics resource on alternative splicing,” Nucleic Acids Research, vol. 34, pp. D46–55, 2006.
- D. Rambaldi, B. Felice, V. Praz, P. Bucher, D. Cittaro, and A. Guffanti, “Splicy: a web-based tool for the prediction of possible alternative splicing events from Affymetrix probeset data,” BMC Bioinformatics, vol. 8, no. 1, article no. S17, 2007.
- S. Foissac and M. Sammeth, “ASTALAVISTA: dynamic and flexible analysis of alternative splicing events in custom gene datasets,” Nucleic Acids Research, vol. 35, pp. W297–299, 2007.
- Z. Lacroix, C. Legendre, L. Raschid, and B. Snyder, “BIPASS: BioInformatics Pipeline Alternative Splicing Services,” Nucleic Acids Research, vol. 35, pp. W292–296, 2007.
- Y. Lee, Y. Lee, B. Kim et al., “ECgene: an alternative splicing database update,” Nucleic Acids Research, vol. 35, no. 1, pp. D99–D103, 2007.
- A. Bhasi, R. V. Pandey, S. P. Utharasamy, and P. Senapathy, “EuSplice: a unified resource for the analysis of splice signals and alternative splicing in eukaryotic genes,” Bioinformatics, vol. 23, no. 14, pp. 1815–1823, 2007.
- M. C. Ryan, B. R. Zeeberg, N. J. Caplen et al., “SpliceCenter: a suite of web-based bioinformatic applications for evaluating the impact of alternative splicing on RT-PCR, RNAi, microarray, and peptide-based studies,” BMC Bioinformatics, vol. 9, article 313, 2008.
- T. Castrignanò, M. D'Antonio, A. Anselmo et al., “ASPicDB: a database resource for alternative splicing analysis,” Bioinformatics, vol. 24, no. 10, pp. 1300–1304, 2008.
- J. M. Bechtel, P. Rajesh, I. Ilikchyan et al., “The Alternative Splicing Mutation Database: a hub for investigations of alternative splicing using mutational evidence,” BMC Research Notes, vol. 1, article 3, 2008.
- F. Birzele, R. Küffner, F. Meier, F. Oefinger, C. Potthast, and R. Zimmer, “ProSAS: a database for analyzing alternative splicing in the context of protein structures,” Nucleic Acids Research, vol. 36, no. 1, pp. D63–D68, 2008.
- M. Floris, M. Orsini, and T. A. Thanaraj, “Splice-mediated variants of proteins (SpliVaP)—data and characterization of changes in signatures among protein isoforms due to alternative splicing,” BMC Genomics, vol. 9, article 453, 2008.
- A. Bhasi, P. Philip, V. T. Sreedharan, and P. Senapathy, “AspAlt: a tool for inter-database, inter-genomic and user-specific comparative analysis of alternative transcription and alternative splicing in 46 eukaryotes,” Genomics, vol. 94, no. 1, pp. 48–54, 2009.
- G. Koscielny, V. L. Texier, C. Gopalakrishnan et al., “ASTD: the Alternative Splicing and Transcript Diversity database,” Genomics, vol. 93, no. 3, pp. 213–220, 2009.
- R. Sinha, T. Lenser, N. Jahn et al., “TassDB2: a comprehensive database of subtle alternative splicing events,” BMC Bioinformatics, vol. 11, article 216, 2010.
- J. I. Takeda, Y. Suzuki, R. Sakate et al., “H-DBAS: Human-transcriptome database for alternative splicing: update 2010,” Nucleic Acids Research, vol. 38, no. 1, Article ID gkp984, pp. D86–D90, 2009.
- J. E. Kroll, P. A. Galante, D. T. Ohara, F. C. Navarro, L. Ohno-Machado, and S. J. de Souza, “SPLOOCE: a new portal for the analysis of human splicing variants,” RNA Biology, vol. 9, no. 11, pp. 1339–1343, 2012.
- J. M. Rodriguez, P. Maietta, I. Ezkurdia et al., “APPRIS: annotation of principal and alternative splice isoforms,” Nucleic Acids Research, vol. 41, pp. 110–117, 2013.
- F. Piva, M. Giulietti, A. B. Burini, and G. Principato, “SpliceAid 2: a database of human splicing factors expression data and RNA target motifs,” Human Mutation, vol. 33, no. 1, pp. 81–85, 2012.
- E. Wingender, T. Schoeps, and J. Donitz, “TFClass: an expandable hierarchical classification of human transcription factors,” Nucleic Acids Research, vol. 41, pp. 165–170, 2013.